for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Biocept Inc

BIOC.OQ

Latest Trade

0.88USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.66

 - 

3.71

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.88
Open
--
Volume
--
3M AVG Volume
9.58
Today's High
--
Today's Low
--
52 Week High
3.71
52 Week Low
0.66
Shares Out (MIL)
23.02
Market Cap (MIL)
20.36
Forward P/E
-0.69
Dividend (Yield %)
--

Next Event

Q3 2019 Biocept Inc Earnings Release

Latest Developments

More

Biocept Q2 Revenue Rose 45% To $1.2 Mln

Biocept Announces Laboratory Services Provider Agreement With Beaconlbs

Biocept Q1 Loss Per Share $0.61

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Biocept Inc

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

Industry

Biotechnology & Drugs

Contact Info

5810 Nancy Ridge Dr

+1.858.3208200

https://biocept.com/

Executive Leadership

David F. Hale

Non-Executive Chairman of the Board

Michael W. Nall

President, Chief Executive Officer, Director

Timothy C. Kennedy

Chief Financial Officer, Senior Vice President of Operations, Corporate Secretary

Lyle J. Arnold

Senior Vice President - Research & Development, Chief Scientific Officer

Edwin C. Hendrick

Senior Vice President, Chief Commercial Officer

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-57.600

2017

-23.700

2018

-9.010

2019(E)

-1.280
Price To Earnings (TTM)
--
Price To Sales (TTM)
5.31
Price To Book (MRQ)
1.55
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
13.44
LT Debt To Equity (MRQ)
6.58
Return on Investment (TTM)
-288.71
Return on Equity (TTM)
-182.96

Latest News

BRIEF-Biocept And Prognos Enter Into Partnership

* BIOCEPT AND PROGNOS ENTER INTO PARTNERSHIP TO APPLY ARTIFICIAL INTELLIGENCE IN ORDER TO HELP PHARMACEUTICAL AND LIFE SCIENCES COMPANIES OPTIMIZE COMMERCIALIZATION OF BIOMARKER-TARGETED THERAPIES IN ONCOLOGY Source text for Eikon: Further company coverage:

BRIEF-Biocept Inc Files For Mixed Shelf Of Up To $50 Million

* BIOCEPT INC FILES FOR MIXED SHELF OF UP TO $50 MILLION – SEC FILING Source http://bit.ly/2wJv6pr Further company coverage:

BRIEF-Biocept Inc Obtains Patent For A Certain Technology In China

* BIOCEPT OBTAINS PATENT FOR ITS TARGET SELECTOR MOLECULAR BIOMARKER TECHNOLOGY IN CHINA Source text for Eikon: Further company coverage:

BRIEF-Biocept Reports Q4 Loss Of $0.18 Per Share

* BIOCEPT REPORTS 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

BRIEF-Biocept And Thermo Fisher Scientific Enter Into Technology And Commercial Collaboration

* BIOCEPT AND THERMO FISHER SCIENTIFIC ENTER INTO TECHNOLOGY AND COMMERCIAL COLLABORATION

BRIEF-Biocept Prices $15 Million Public Offering Of 33.3 Mln Shares and Warrants

* BIOCEPT ANNOUNCES PRICING OF $15.0 MILLION PUBLIC OFFERING OF 33,333,333 SHARES OF COMMON STOCK AND WARRANTS TO PURCHASE 33,333,333 SHARES OF COMMON STOCK

BRIEF-Biocept Offers 18.8 Mln Shares Of Common Stock

* BIOCEPT INC FILES TO SAY IT OFFERING 18.8 MILLION SHARES OF ITS COMMON STOCK AND WARRANTS TO PURCHASE SHARES OF COMMON STOCK - SEC FILING

BRIEF-Biocept Inc Says Signed An In-Network Provider Agreement With Wellmark Inc

* BIOCEPT INC - HAS SIGNED AN IN-NETWORK PROVIDER AGREEMENT WITH WELLMARK INC Source text for Eikon: Further company coverage:

BRIEF-Sabby Management LLC Reports A 9.20 Pct Passive Stake In Biocept

* SABBY MANAGEMENT LLC REPORTS A 9.20 PCT PASSIVE STAKE IN BIOCEPT INC AS OF DEC 5 - SEC FILING Source text: (http://bit.ly/2ACbgue) Further company coverage:

BRIEF-Biocept announces pricing of public offering of up to 4,925,936 shares of common stock

* BIOCEPT ANNOUNCES PRICING OF PUBLIC OFFERING OF UP TO 4,925,936 SHARES OF COMMON STOCK

BRIEF-Biocept And UC San Diego Medical Center Announce Clinical Study Collaboration To Demonstrate Utility Of Biocept's Liquid Biopsy Test In Immunotherapy

* BIOCEPT AND UC SAN DIEGO MEDICAL CENTER ANNOUNCE CLINICAL STUDY COLLABORATION TO DEMONSTRATE UTILITY OF BIOCEPT'S LIQUID BIOPSY TEST IN IMMUNOTHERAPY Source text for Eikon: Further company coverage:

BRIEF-Biocept files for offering $10 mln of shares of co's common stock and warrants

* Biocept Inc files for offering $10 million of shares of co's common stock and warrants - SEC Filing

BRIEF-Biocept reports Q3 loss per share $0.20

* Biocept Inc - cash and cash equivalents were $5.9 million as of September 30, 2017 Source text for Eikon: Further company coverage:

BRIEF-Biocept and Miraca Life Sciences enter into marketing agreement

* Biocept and Miraca Life Sciences enter into marketing agreement to expand target selector testing in the United States

BRIEF-Biocept Inc files for disposition of up to 2.9 million shares of common stock

* Biocept Inc files for disposition of up to 2.9 million shares of common stock by the selling stockholders Source text: (http://bit.ly/2fShoIH) Further company coverage:

BRIEF-Biocept, UT Southwestern Medical Center announce clinical study to profile, monitor non-small cell lung cancer patients

* Biocept and UT Southwestern medical center announce clinical study to profile and monitor non-small cell lung cancer patients with ALK rearrangements Source text for Eikon: Further company coverage:

BRIEF-Biocept enters into distribution agreement with Global Laboratory Product Supplier VWR

* Biocept enters into exclusive distribution agreement with Global Laboratory Product Supplier VWR

BRIEF-Biocept Q2 loss per share $0.21

* Says revenues for Q2 of 2017 increased 93% to $1.3 million

BRIEF-Biocept announces private placement of $2.2 mln of common stock

* Biocept announces private placement of $2.2 million of common stock with Ally Bridge LB Healthcare Master Fund

BRIEF-Biocept executes preferred provider agreement with Scripps Health Plan

* Biocept executes preferred provider agreement with Scripps Health Plan expanding patient coverage for its liquid biopsy platform Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up